0001171000-15-000045.txt : 20150702
0001171000-15-000045.hdr.sgml : 20150702
20150702133257
ACCESSION NUMBER: 0001171000-15-000045
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150701
FILED AS OF DATE: 20150702
DATE AS OF CHANGE: 20150702
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nexvet Biopharma plc
CENTRAL INDEX KEY: 0001618561
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: NATL INST FOR BIOPROCESSING RESEARCH
STREET 2: FOSTERS AVENUE, MOUNT MERRION
CITY: BLACKROCK CO. DUBLIN
STATE: L2
ZIP: 00000
BUSINESS PHONE: 353 1 215 8100
MAIL ADDRESS:
STREET 1: NATL INST FOR BIOPROCESSING RESEARCH
STREET 2: FOSTERS AVENUE, MOUNT MERRION
CITY: BLACKROCK CO. DUBLIN
STATE: L2
ZIP: 00000
FORMER COMPANY:
FORMER CONFORMED NAME: NEXVET BIOPHARMA Ltd
DATE OF NAME CHANGE: 20140903
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lismore Damian T.
CENTRAL INDEX KEY: 0001560864
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36828
FILM NUMBER: 15968506
MAIL ADDRESS:
STREET 1: 12270 WILKINS AVENUE
CITY: ROCKVILLE
STATE: MD
ZIP: 20852
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2015-07-01
0001618561
Nexvet Biopharma plc
NVET
0001560864
Lismore Damian T.
C/O NEXVET BIOPHARMA PLC
NIBRT; FOSTERS AVENUE, MOUNT MERRION
BLACKROCK, CO. DUBLIN
L2
IRELAND
0
1
0
0
CHIEF FINANCIAL OFFICER
Ordinary Shares
2015-07-01
4
M
0
4000
.125
A
10000
D
Ordinary Shares
13724
I
Glenariff Superannuation Pty Ltd <Glenariff Super Fund A/C>
Ordinary Shares
7080
I
By spouse
Options to Purchase Stock
.125
2015-07-01
4
M
0
4000
0
D
2015-07-01
2019-07-01
Ordinary Shares
4000
14000
D
The reporting person and his spouse share voting and dispositive power with respect to these reported securities.
4,000 options vested and became exercisable on 7/1/15; 4.000 options shall vest and become exercisable on each of 7/1/16 and 7/1/17. The remaining 6,000 options will vest and be exercisable upon successful completion of an efficacy trial for any Issuer product, as determined by the Issuer's board of directors; such completion must occur on or before 7/1/19
/s/ Damian Lismore by Geraldine T. Farrell, Attorney-in-Fact
2015-07-02